KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Equivalents (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash & Equivalents for 17 consecutive years, with $529.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 8.54% to $529.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $529.8 million, a 8.54% increase, with the full-year FY2025 number at $529.8 million, up 8.54% from a year prior.
  • Cash & Equivalents was $529.8 million for Q4 2025 at Bio-Rad Laboratories, up from $395.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $859.9 million in Q3 2021 to a low of $369.3 million in Q2 2025.
  • A 5-year average of $517.9 million and a median of $467.5 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 42.15% in 2023, then grew 20.88% in 2024.
  • Bio-Rad Laboratories' Cash & Equivalents stood at $470.8 million in 2021, then decreased by 7.77% to $434.2 million in 2022, then dropped by 7.0% to $403.8 million in 2023, then rose by 20.88% to $488.1 million in 2024, then grew by 8.54% to $529.8 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Cash & Equivalents are $529.8 million (Q4 2025), $395.8 million (Q3 2025), and $369.3 million (Q2 2025).